Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Tricida, Inc. (TCDA)  
$0.00 0.00 (0.00%) as of 4:30 Tue 6/13


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 50,050,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.00001 - $0.01465
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Tricida is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, Veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI) tract. Veverimer is a non-absorbed, low-swelling, spherical polymer. It is a single, high molecular weight, crosslinked polyamine molecule. Veverimer is designed to specifically bind and remove hydrochloric acid from the GI tract. Acid binding and removal from the GI tract is an approach to treating metabolic acidosis without introducing deleterious counterions or metals.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,822,579
Total Buy Value $0 $0 $0 $40,024,734
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 39
Total Shares Sold 0 0 0 7,304,829
Total Sell Value $0 $0 $0 $13,749,804
Total People Sold 0 0 0 3
Total Sell Transactions 0 0 0 13
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 88
  Page 4 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Coufal Sandra I Director   –       •       •   2021-03-10 4 AS $4.79 $23,950 D/D (5,000) 157,509 -16%     
   Coufal Sandra I Director   –       •       •   2021-02-24 4 AS $8.01 $801 D/D (100) 162,509 -46%     
   Klaerner Gerrit President and CEO   •       •      –    2021-02-08 4 AS $7.26 $58,080 D/D (8,000) 499,993 -35%     
   Coufal Sandra I Director   –       •       •   2021-02-03 4 AS $6.91 $34,550 D/D (5,000) 162,609 -26%     
   Coufal Sandra I Director   –       •       •   2021-01-26 4 AS $7.06 $35,300 D/D (5,000) 167,609 -31%     
   Klaerner Gerrit President and CEO   •       •      –    2021-01-14 4 AS $7.18 $11,883 D/D (1,655) 507,993 -36%     
   Klaerner Gerrit President and CEO   •       •      –    2021-01-13 4 AS $7.41 $111,409 D/D (15,035) 509,648 -38%     
   Klaerner Gerrit President and CEO   •       •      –    2021-01-12 4 AS $7.65 $75,131 D/D (9,821) 524,683 -38%     
   Klaerner Gerrit President and CEO   •       •      –    2021-01-11 4 AS $7.49 $160,953 D/D (21,489) 534,504 -35%     
   Coufal Sandra I Director   –       •       •   2020-12-14 4 S $7.90 $395,000 D/D (50,000) 172,609 39%     
   Mckague Robert EVP, General Counsel   •       –      –    2020-12-11 4 B $7.62 $76,200 I/I 10,000 10,000 1.99 -38%     
   Parker Geoffrey M. CFO and EVP   •       –      –    2020-12-10 4 B $6.78 $101,700 I/I 15,000 40,000 1.99 -30%     
   Yoshiyama Annie VP, Finance and CAOOfficer   •       –      –    2020-12-04 3 IO $0.00 $0 D/D 0 2,016 -39%     

  88 Records found
  1  2  3  4    
  Page 4 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed